Category Archives: Immunology

Viral evolution in animals could reveal future of COVID-19 – Jill Lopez

When animals catch COVID-19 from humans, new SARS-CoV-2 variants can arise. To evaluate this phenomenon, an interdisciplinary team at the College of Veterinary Medicine and Biomedical Sciences systematically analyzed mutation types occurring in the virus after infection of cats, dogs, ferrets, and hamsters.

Confirmed COVID-19 cases in a variety of wild, zoo, and household animals demonstrate cross-species transmission, which is a rare occurrence for most viruses.

SARS-CoV-2, in the realm of coronaviruses, has a very broad species range, said Laura Bashor, one of the first authors and a doctoral student in the Department of Microbiology, Immunology and Pathology. Generally speaking, many types of viruses cant infect other species of animals, they evolved to be very specific.

Humans have so much exposure to many different animals which permitted this virus to have the opportunity to expose a variety of different species, said Erick Gagne, a first author and now an assistant professor of wildlife disease ecology at the University of Pennsylvania.

The global reach and spillover of the virus have given researchers a unique opportunity to investigate the viral evolution of SARS-CoV-2, including in University Distinguished Professor Sue VandeWoudes laboratory at Colorado State University.

These specialists in disease transmission in wild and domestic cats applied their experience in sequence analysis and studying a collection of genomes to SARS-CoV-2.The studywas recently published in PNAS, the official journal of the National Academy of Sciences.

Researchers in the VandeWoude lab worked with Assistant Professor Angela Bosco-Lauth and Professor Dick Bowen in the Department of Biomedical Sciences, who used their animal modeling expertise to develop a test for SARS-CoV-2 susceptibility of animal species.

Also key to the findings was a newer sequencing technique of the virus at different stages of the study, now common to detect variants in the human population. Mark Stenglein, associate professor in the Department of Microbiology, Immunology, and Pathology, provided computational skills in analyzing biological molecule sequences, known as bioinformatics, to the study.

We found there was evolution, we saw selection on the virus, and we saw a lot of variants emerge in the genome sequence of the virus, said Bashor.

To provide ample viral material for the study, Bosco-Lauth and Bowen cultivated a SARS-CoV-2 human sample in cells grown in the lab. Bashor and Gagne determined that multiple mutations developed, and became a greater percentage of the genetic population, at each step of this process.

Then the virus was introduced to the four household species, and samples of the virus were collected from their nasal passages after infection.

In the animals, the cell culture variants reverted back to the initial human type, which indicates that likely there is adaption occurring in that cell culture and environment that was selected for those variants, said Gagne.

Not all these mutations within the cell culture SARS-CoV-2 variant transferred in the new hosts. Instead, different mutations emerged within the virus shed by the live animals.

The initial viral sample in the study was isolated in early 2020. The team observed mutations that have since formed wide-spread SARS-CoV-2 strains in the human population at an accelerated rate throughout the study.

Among those were a number that weve since seen in humans in the alpha, beta, delta variants, said Dr. Sue VandeWoude, senior author. There were specific genetic code changes that mimicked what other scientists have reported in people.

Contact exposure between two cats demonstrated the SARS-CoV-2 variant can be transmitted with the possibility of producing a new strain within the species.

Thats what were seeing in people too, said Bosco-Lauth. Hosts that are really well adapted to support SARS-CoV-2 infection are also very good at allowing these mutations to stick and to be passed on.

Bashor did not anticipate studying SARS-CoV-2 when she came to CSU to begin her doctoral studies during the pandemic. However, it provided a unique opportunity to hit the ground running as a graduate student on a really cool and viable project in disease ecology and evolution.

Gagne was completing his postdoctoral research on cross-species transmission of feline retroviruses in the VandeWoude lab when the team launched the SARS-CoV-2 study. Now an assistant professor, he has continued to investigate SARS-CoV-2 spillover with the Wildlife Futures Program at the University of Pennsylvania.

Graduate students and early career scientists like Bashor and Gagne, have made meaningful contributions to SARS-CoV-2 research, said VandeWoude.

The team has continued their investigations to focus on cats, as they have shown higher susceptibility for COVID-19 spillover from humans and can produce variants of the virus and spread to other cats.

Bashor began analyzing SARS-CoV-2 genome sequences from a large pool of cat species all over the world, including tigers, lions and snow leopards. The publicly available data of infected cats could provide additional insights on the adaptability and mutability of COVID-19 within and among cat species.

There is not evidence of transmission from cats to humans. But cats continue to be susceptible to all variants of COVID-19 in the human population.

Read this article:
Viral evolution in animals could reveal future of COVID-19 - Jill Lopez

Analysis shows skin peanut allergy patch safe and well tolerated over 3-year period – Hospital Healthcare Europe

The use of Viaskin, an epicutaneous patch used for children with a peanut allergy appears to be safe and well tolerated according to a three-year analysis presented by at the American College of Allergy, Asthma and Immunology Conference, November 2021.

A peanut allergy is thought to affect around 2% of the general population and in a study of 3218 children, the incidence was found to be 24.8%. The presence of a peanut allergy is challenging for those affected and requires a high level of vigilance directed towards the avoidance of accidental ingestion of peanut-containing foods.

The use of viaskin represents epicutaneous immunotherapy and according to the manufacturer, DBV Technologies, is a proprietary technology platform that enables the delivery of biologically active compounds to the immune system through the skin.

The data presented at the American College of Allergy, Asthma and Immunology Conference was based on the REALISE trial, which included children with documented histories of peanut anaphylaxis and who were randomised, 3:1, to either viaskin peanut 250mcg (which contains 1/1000th of the protein found in a single peanut) or a placebo for a period of 6 months. Once this initial phase was completed, all subjects continued to receive the active treatment in an open-label extension, for a period of three years. For the REALISE study, the primary outcome was set as adverse Events (AEs), treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) throughout the study period.

The 6-month safety data for viaskin has already been published and showed that the patch was well-tolerated.

Findings

REALISE recruited 393 children with a median age of 7 years (gender not reported) of whom, 14 (3.6%) had a history of severe anaphylaxis. Throughout the study period, most subjects experienced at least one TEAE although these were reported as being mild (97.4%) or moderate (70.4%) in severity and commonly consisted of application site erythema and pruritus which fortunately decreased over time.

Overall, 16 children experienced a total of 17 anaphylactic reactions (none severe) considered to be due to viaskin. In addition, there were 2 serious that were viakskin-related TEAEs (2 anaphylactic reactions: one leading to permanent study discontinuation). No difference in TEAEs in subjects with severe anaphylaxis history was apparent.

The authors concluded that over 36-months, Viaskin Peanut was generally well tolerated, with decreasing frequency and intensity of local and systemic treatment-related AEs over time.

The product is yet to be approved by the FDA, which has requested more data or the EMA.

Citation

Brown-Whitehorn T et al. D030 REALISE (REAL-LIFE USE AND SAFETY OF EPIT) STUDY: 3 YEAR RESULTS IN PEANUT-ALLERGIC CHILDREN. Ann Allergy Asthma Immunol 2021

See the article here:
Analysis shows skin peanut allergy patch safe and well tolerated over 3-year period - Hospital Healthcare Europe

VBI Vaccines Announces FDA Approval of PreHevbrio for the Prevention of Hepatitis B in Adults – Yahoo Finance

- PreHevbrio is the only approved 3-antigen hepatitis B vaccine for adults in the U.S.

- Shareholder conference call to be held today, December 1, at 8:30 AM ET

CAMBRIDGE, Mass., December 01, 2021--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the U.S. Food and Drug Administration (FDA) has approved PreHevbrio [Hepatitis B Vaccine (Recombinant)] for the prevention of infection caused by all known subtypes of hepatitis B virus (HBV) in adults age 18 years and older. PreHevbrio contains the S, pre-S2, and pre-S1 HBV surface antigens, and is the only approved 3-antigen HBV vaccine for adults in the U.S.

"As we work to implement the ACIPs new universal hepatitis B vaccine recommendation for all adults ages 19-59, as voted on in November, we benefit from having more tools, including this newly approved 3-antigen hepatitis B vaccine," said Chari Cohen, DrPH, MPH, Senior Vice President of the Hepatitis B Foundation. "Having more vaccine options will help us effectively expand vaccine uptake, ensure more people are protected from hepatitis B infection, and reach the 2030 goal of eliminating hepatitis B in the U.S."

Jeff Baxter, VBIs President and CEO, commented: "We are proud to announce the approval of PreHevbrio, VBIs first FDA-approved vaccine. This is a substantial achievement that demonstrates the VBI teams ability to progress vaccine candidates from the clinic through to approval. This approval, however, is just the first step in our mission to provide broad access to our vaccine and to help strengthen the public health effort to put an end to adult HBV infections. We would like to thank the study participants, clinical site investigators, our employees, and all who contributed to this achievement, and we look forward to working with public health and advocacy organizations as we join the fight against hepatitis B."

Story continues

The approval of PreHevbrio was based on the results from two Phase 3 clinical studies, PROTECT and CONSTANT, data from which were published, respectively, in The Lancet Infectious Diseases in May 2021 and The Journal of the American Medical Association Network Open in October 2021. The pivotal studies compared PreHevbrio to Engerix-B, a single-antigen HBV vaccine. Data from the PROTECT study showed that PreHevbrio elicited higher rates of seroprotection in all subjects age 18+ (91.4% vs. 76.5%), including in adults age 45+ (89.4% vs. 73.1%). The integrated safety analysis of both studies demonstrated good tolerability with no unexpected reactogenicity. The most common adverse events in all age groups were injection site pain and tenderness, myalgia, and fatigue, all which generally resolved without intervention in 1-2 days.

VBI expects to make PreHevbrio available in the U.S. in the first quarter of 2022, and has partnered with Syneos Health for the past two years to ensure commercial readiness.

Outside of the U.S., VBI continues to support the European Medicines Agencys (EMA) ongoing review of the marketing authorization application for VBIs 3-antigen HBV vaccine. VBI expects to complete regulatory submissions to the United Kingdoms Medicines and Healthcare products Regulatory Agency (MHRA) and to Health Canada in 2022.

Conference Call Details

VBI Vaccines will host a conference call on Wednesday, December 1 at 8:30 AM ET. The live call can be accessed via the Events/Presentations page in the Investors section of the Companys website, or by clicking this link: https://viavid.webcasts.com/starthere.jsp?ei=1517423&tp_key=00a076a769.

A replay of the conference call will be archived on the Companys website following the live call.

To listen to the live conference call, please dial:

- Toll-free U.S. & Canada Dial-In: 877-705-6003

- International Dial-In: 201-493-6725

- Conference ID: 13725342

Indication and Use

PreHevbrio is indicated for prevention of infection caused by all known subtypes of hepatitis B virus. PreHevbrio is approved for use in adults 18 years of age and older.

Important Safety Information (ISI)

Do not administer PreHevbrio to individuals with a history of severe allergic reaction (e.g. anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of PreHevbrio.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of PreHevbrio.

Immunocompromised persons, including those on immunosuppressant therapy, may have a diminished immune response to PreHevbrio.

PreHevbrio may not prevent hepatitis B infection, which has a long incubation period, in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common side effects (> 10%) in adults age 18-44, adults age 45-64, and adults age 65+ were pain and tenderness at the injection site, myalgia, fatigue, and headache.

There is a pregnancy exposure registry that monitors pregnancy outcomes in women who received PreHevbrio during pregnancy. Women who receive PreHevbrio during pregnancy are encouraged to contact 1-888-421-8808 (toll-free).

To report SUSPECTED ADVERSE REACTIONS, contact VBI Vaccines at 1-888-421-8808 (toll-free) or VAERS at 1-800-822-7967 or http://www.vaers.hhs.gov

Please see full Prescribing Information.

About Hepatitis B

Hepatitis B is one of the worlds most significant infectious disease threats with more than 290 million people infected globally. HBV infection is the leading cause of liver disease and, with current treatments, it is very difficult to cure, with many patients going on to develop liver cancers. An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma.

Earlier in November 2021, the U.S. Centers for Disease Control and Preventions (CDC) Advisory Committee on Immunization Practices (ACIP) unanimously voted to recommend universal HBV vaccination for adults age 18 to 59, and for adults age 60+ with risk factors for infection, expanding the addressable adult population that should be vaccinated.

About PreHevbrio

PreHevbrio is an adult hepatitis B vaccine that contains the three hepatitis B surface antigens of the hepatitis B virus S, pre-S1, and pre-S2. PreHevbrio is also approved for use and commercially available in Israel under the brand name Sci-B-Vac.

About VBI Vaccines Inc.

VBI Vaccines Inc. ("VBI") is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles ("VLPs"), including a proprietary enveloped VLP ("eVLP") platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

Website Home: http://www.vbivaccines.com/

News and Resources: http://www.vbivaccines.com/news-and-resources/

Investors: http://www.vbivaccines.com/investors/

Cautionary Statement on Forward-looking Information

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, "forward-looking statements"). The Company cautions that such statements involve risks and uncertainties that may materially affect the Companys results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the impact of general economic, industry or political conditions in the United States or internationally; the impact of the ongoing COVID-19 pandemic on our clinical studies, manufacturing, business plan, and the global economy; the ability to successfully manufacture and commercialize PreHevbrio; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of pipeline candidates and the commercialization of PreHevbrio; the ability to obtain appropriate or necessary regulatory approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Companys ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Companys products. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Companys filings with the SEC and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the SEC on March 2, 2021, and filed with the Canadian security authorities at sedar.com on March 2, 2021, as may be supplemented or amended by the Companys Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005387/en/

Contacts

VBINicole AndersonDirector, Corporate Communications & IRPhone: (617) 830-3031 x124Email: IR@vbivaccines.com

See more here:
VBI Vaccines Announces FDA Approval of PreHevbrio for the Prevention of Hepatitis B in Adults - Yahoo Finance

Everything We Know and Don’t Know About the Omicron Variant – WDET

This week, Michigan hit a dreadful milestone. The statehasthe highest numberof adults hospitalized with COVID-19 since the pandemic began, even as vaccines are widelyavailable.

I think its important for everyone to remember that we know so little right now. Adam Lauring, microbiologist at University ofMichigan

Now, many Michiganders and Americans are worried about anew variantthat has emerged and is spreading around theworld.

Adam Lauringis an associate professor of microbiology and immunology, and infectious diseases at the University of Michigan medical school. I think its important for everyone to remember that we know so little right now, hesays.

Laurings lab uploads the second most variant data in Michigan behind the state lab. He says some viral mutations are much more important than others, which is contingent upon how quickly the new virus spreads and the lethality that it brings withit.

WDET strives to make our journalism accessible to everyone. As a public media institution, we maintain our journalistic integrity through independent support from readers like you. If you value WDET as your source of news, music and conversation, please make a gift today.

Donate today

Continued here:
Everything We Know and Don't Know About the Omicron Variant - WDET

Letter to the editor | In support of Hakeem Jefferson and the Early Career Black Faculty Group – The Stanford Daily

To our Stanford Community,

In response to the recent racist attacks on Professor Hakeem Jefferson and the open letter published in The Stanford Daily from the Early Career Black Faculty Group, we, the chairs of the Basic Bioscience Departments in the Stanford Schools of Medicine, Humanities and Sciences, and Engineering, the directors of the Biosciences Institutes and the directors of the Interdisciplinary Biosciences Programs, express our support for Professor Jefferson and the requests made in the open letter. We condemn the coordinated, racist attacks against Professor Jefferson and call on ourselves, our community and our University to help protect and defend our Black colleagues in response to these attacks. We commit to developing proactive strategies, in coordination with our Black faculty, to prevent these attacks in the future, and when we cannot prevent them, to respond to them quickly and to mitigate their negative impacts. We hope that we can help Stanford become a community where all of our members feel safe and included as we pursue our scholarly endeavors and career aspirations.

Chairs of Basic Biomedical Science Departments in the Schools of Medicine, Engineering,and Humanities and Science, directors of the Biosciences Institutes and the directors of the Interdisciplinary Biosciences Programs

Stephen A. Baccus Chair, Department of Neurobiology

Melissa L. Bondy Chair, Department of Epidemiology and Population Health

James K. Chen Chair, Department of Chemical and Systems Biology

Jennifer R. Cochran Chair, Department of Bioengineering

Martha S. Cyert Chair, Department of Biology

Miriam B. Goodman Chair, Department of Molecular and Cellular Physiology

Sherril L. Green Chair, Department of Comparative Medicine

Theodore S. Jardetzky Chair, Department of Structural Biology

Paul S. Mischel Vice Chair for Research, Department of Pathology

Thomas Montine Chair, Department of Pathology

Douglas K. Owens Chair, Department of Health Policy

Sylvia K. Plevritis Chair, Department of Biomedical Data Science

David S. Schneider Chair, Department of Microbiology and Immunology

Michael Snyder Chair, Department of Genetics

AaronF. Straight Chair, Department of Biochemistry

Anne Villeneuve Chair, Department of Developmental Biology

Steven Artandi Director, Stanford Cancer Institute

Carolyn Bertozzi Director, ChEM-H Institute

Mark M. Davis Director, Institute for Immunity, Transplantation, and Infection

Mary Leonard Director, Maternal and Child Health Research Institute

Crystal Mackall Director, Parker Institute for Cancer Immunotherapy

William Newsome Director, Wu Tsai Neuroscience Institute

Carla Shatz Director, Bio-X Program

Irving Weissman Director, Institute for Stem Cell Biology and Regenerative Medicine

Joseph C. Wu Director, Cardiovascular Institute

Olivia Martinez Director, Immunology Interdisciplinary Graduate Program

K.C. Huang Director, Biophysics Interdisciplinary Graduate Program

Tushar Desai Co-Director, Stem Cell Biology and Regenerative Medicine Interdisciplinary Graduate Program

Gerald Spangrude Co-Director, Stem Cell Biology and Regenerative Medicine Interdisciplinary Graduate Program

Julien Sage Co-Director, Cancer Biology Interdisciplinary Graduate Program

Laura Attardi Co-Director, Cancer Biology Interdisciplinary Graduate Program

Justin Gardner Co-Director, Neurobiology Interdisciplinary Graduate Program

Merritt Maduke Co-Director, Neurobiology Interdisciplinary Graduate Program

Link:
Letter to the editor | In support of Hakeem Jefferson and the Early Career Black Faculty Group - The Stanford Daily

Robert Koch Prize in Microbiology and Immunology Goes to Andreas Bumler – UC Davis

Microbiologist Andreas Bumler of the School of Medicine and the College of Biological Sciences has been named a recipient of the 2021 Robert Koch Prize, given by Germanys Robert Koch Foundation for achievement in microbiology and immunology a prize that is considered one of the most prestigious awards in science.

Bumler is a professor and vice chair of research in the Department of Medical Microbiology and Immunology, and also affiliated with four graduate groups: Microbiology; Immunology; Integrative Pathobiology; and Biochemistry, Molecular, Cellular and Developmental Biology.

He shares the prize with Yasmine Belkaid, immunologist and senior investigator at the National Institute of Allergy and Infectious Diseases, and adjunct professor at the University of Pennsylvania.

The Robert Koch Prize is shared this year to recognize groundbreaking research that shows how, on the one hand, our microflora train our immune system, and on the other hand, our intestinal epithelium determines the composition of our microflora, and what role disruptions of this dialogue between microflora and us play in infectious and inflammatory diseases, the foundation said in a news release.

UC Davis Professor Satya Dandekar, chair of the Department of Medical Microbiology and Immunology, said: Dr. Bumler has made seminal contributions for advancing our knowledge of the microbial dysbiosis during gut inflammatory infections. He is an exceptional scientist and a great mentor to junior researchers.

The award ceremony is scheduled for Nov. 19 in Berlin. As of today (Nov. 8), the prize of 120,000 euros is the equivalent of $139,075.

Wolfgang Plischke, chair of the Robert Koch Foundation, said: At a time when science and research are constantly at the center of public interest and are often the subject of unfiltered discussion on social networks, it is more important than ever to honor the hard work, unwavering diligence and thirst for knowledge of all the men and women who have dedicated their lives to medicine and biology.

Robert Koch (18431910), after whom the prize is named, founded modern bacteriology. For this he received the Nobel Prize for Medicine and Physiology in 1905. Koch headed the Institute for Infectious Diseases in Berlin from 1891 until his retirement in 1904.

View original post here:
Robert Koch Prize in Microbiology and Immunology Goes to Andreas Bumler - UC Davis

Oncology meets immunology: the cancer-immunity cycle

The genetic and cellular alterations that define cancer provide the immune system with the means to generate T cell responses that recognize and eradicate cancer cells. However, elimination of cancer by T cells is only one step in the Cancer-Immunity Cycle, which manages the delicate balance between the recognition of nonself and the prevention of autoimmunity. Identification of cancer cell T cell inhibitory signals, including PD-L1, has prompted the development of a new class of cancer immunotherapy that specifically hinders immune effector inhibition, reinvigorating and potentially expanding preexisting anticancer immune responses. The presence of suppressive factors in the tumor microenvironment may explain the limited activity observed with previous immune-based therapies and why these therapies may be more effective in combination with agents that target other steps of the cycle. Emerging clinical data suggest that cancer immunotherapy is likely to become a key part of the clinical management of cancer.

Go here to see the original:
Oncology meets immunology: the cancer-immunity cycle

Biovaxys says CoviDTH shows safety and tolerability in pathology and immunology evaluations – Proactive Investors USA & Canada

BioVaxys Technology Corp Chief Medical Officer David Berd joined Proactive to discuss results from its in vivo animal research study support the safety and tolerability of CoviDTH at two intradermal dose levels across a battery of clinical pathology, immunology, and histopathology evaluations.

CoviDTH is the world's first and only low-cost, disposable, point-of-care diagnostic tool that screens for a T-cell response to SARS-CoV-2, the virus that causes coronavirus, according to BioVaxys.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

Read the original:
Biovaxys says CoviDTH shows safety and tolerability in pathology and immunology evaluations - Proactive Investors USA & Canada

The Science Behind COVID-19 Vaccines & Immunology – News | University Communication | Nebraska

Increase your understanding of the science behind biology and immunology, along with how scientists use that information to develop vaccines and how these vaccines work in our bodies. Plan to attend this interesting and informal educational session with Dr. Angie Pannier, a biomedical engineer and expert in nucleic acid vaccines, and Dr. Amanda Ramer-Tait, an immunologist and expert on host-microbe interactions.

Whether youre a budding researcher yourself or youd like to increase your scientific knowledge to share with family and friends, this session will break down the basics of how vaccines work. The first 45 minutes will provide an overview and the second half of the session will offer time for Q&A.

Read the original:
The Science Behind COVID-19 Vaccines & Immunology - News | University Communication | Nebraska

Correction for Wolfsberger et al., TAp73 represses NF-Bmediated recruitment of tumor-associated macrophages in breast cancer – pnas.org

IMMUNOLOGY AND INFLAMMATION Correction for TAp73 represses NF-Bmediated recruitment of tumor-associated macrophages in breast cancer, by Johanna Wolfsberger, Habib A. M. Sakil, Leilei Zhou, Niek van Bree, Elena Baldisseri, Sabrina de Souza Ferreira, Veronica Zubillaga, Marina Stantic, Nicolas Fritz, Johan Hartman, Charlotte Rolny, and Margareta T. Wilhelm, which published March 1, 2021; 10.1073/pnas.2017089118 (Proc. Natl. Acad. Sci. U.S.A. 118, e2017089118).

The authors note that Supporting Table S2 in the SI Appendix appeared incorrectly. Regarding this error, the authors note, Sanger sequencing primers for the mouse and human Ccl2 gene have mistakenly been entered in the qPCR primer table (SI Appendix, Table S2) instead of the qPCR primer sequences for Ccl2 that were used in this study.

The authors also note that an error appeared in Fig. 3 and Fig. S3 in the SI Appendix. In both figures, the histograms are labeled DMSO but should instead be labeled siCtrl. The corrected figure and its legend appear below. The online version has been corrected, including the SI Appendix with the corrected Table S2 and Fig. S3.

TAp73 represses NF-Bmediated regulation of Ccl2 expression. (A) qRT-PCR analysis of Ccl2 mRNA levels in (A) TAp73 WT and KO MEFE1A/Ras (n = 3) and (B) PyMT/TAp73 WT or KO cells (n = 4) after 16-h treatment with NF-B inhibitor SC-514 (100 g/mL). ELISA analysis of Ccl2 protein secretion in conditioned media from (C) TAp73 WT and KO MEFE1A/Ras (n = 3) and (D) PyMT/TAp73 WT or KO cells (n = 4) after 16-h treatment with SC-514 (100 g/mL). (E and F) qRT-PCR analysis of Ccl2 mRNA levels in (E) TAp73 WT and KO MEFE1A/Ras (n = 3) and (F) PyMT/TAp73 WT or KO cells (n = 3) after 48-h treatment with sip65/RELA. (G and H) ELISA analysis of Ccl2 protein secretion in conditioned media from (G) TAp73 WT and KO MEFE1A/Ras (n = 3) and (H) PyMT/TAp73 WT or KO cells (n = 3) after 48-h treatment with sip65/RELA. (I) Schematics showing the murine Ccl2 promoter including NF-B response elements, of which the distal BSs 3 and 4 were deleted either individually or simultaneously. (J) WT or mutated Ccl2 promoter luciferase reporter was cotransfected with TAp73 in HEK293 cells. Luciferase activity was measured 24 h after transfection and normalized to mock control (n = 6). All data are shown as mean SD *P < 0.05, **P < 0.01, ****P < 0.0001.

See the original post:
Correction for Wolfsberger et al., TAp73 represses NF-Bmediated recruitment of tumor-associated macrophages in breast cancer - pnas.org